BioSpace News Archive

CVS Health announced that Michelle Peluso will join the company as Chief Customer Officer effective January 25. In this newly created executive leadership role, Peluso will be responsible for transforming the consumer experience and accelerating CVS Health’s digital strategy.

- ultraVIOLET Evaluated the Efficacy and Safety of Oteseconazole over 50 weeks - - Efficacy of Oteseconazole Compared to Fluconazole in Treating Acute VVC Infection in Women with RVVC - - NDA Submission Planned in First Half of 2021 -

− Concentrated molybdenum-98 (cMo-98) enables up to four-fold increase of critical medical radioisotope Mo-99 production in U.S. – − First and only commercial-scale application of innovative cMo-98 production technology –

Jaguar Health, Inc. announced that the 28-day preclinical toxicology and safety study in dogs began today, January 6, 2021, to support development of lechlemer, the second generation, plant-based anti-secretory drug candidate of Napo Pharmaceuticals, Jaguar’s wholly owned subsidiary, for the symptomatic relief of diarrhea from cholera.

Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce that it is one of only four companies selected to receive advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the company’s development of its antiviral asset, BOLD-100,

-Highlights of Continued Execution of Plans for Multiple Clinical Programs and Upcoming Catalysts -Additions to the Clinical, Operational and Regulatory Teams

Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People’s Republic of China has approved a Clinical Trial Application (CTA) for sacituzumab govitecan-hziy

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that members of its executive leadership team will virtually present at the 39th Annual J.P. Morgan Healthcare Conference at 8:20 a.m. ET on January 11, 2021. A live webcast of the presentation

American BriVision Corporation, a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system, and ophthalmology, yesterday issued a letter to its more than 700 shareholders describing the company’s achievements in 2020 and goals for 2021.

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Dr. Claus Møller, MD, Ph.D., Chief Executive Officer of Y-mAbs Therapeutics will provide an overview and update on the company’s business at the virtual 39th Annual J.P. Morgan Healthcare Confere